Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Acta Academiae Medicinae Militaris Tertiae》 2002-12
Add to Favorite Get Latest Update

Clinical study of small dose of topotecan combined with cisplatin in the treatment of advanced squamous carcinoma of lung

LIU Gang, WANG Zheng hui, YANG He ping, HU Jian lin, LIU Ping (Department of respiratory diseases,Southwest Hospital, Third Military Medical University, Chongqing 400038, China)  
Objective To evaluate the therapeutic efficacy and toxicity of the combination of topotecan and cisplatin in the treatment of patients with advanced sqamous carcinoma of lung. Methods Thirty eight patients with stage III or stage IV squamous carcinoma of lung confirmed pathohistologically or cytologically were administered intravenously with 0.8 mg/m 2 topotecan on day 1-5, and 50-70 mg/m 2 cisplatin on day 6 of the 21 day cycle. Results The total effective rate was 44.7%, among them 17 was partial responses, whereas 15 patients stable and 6 patients were progressive. The response rate of 27 patients without prior chemotherapy and 11 patients with chemotherapy was 48.1% and 36.4%, respectively. No significant difference was found between the two groups ( P 0.05). The median duration of survival was 10 months, and 1 year survival rate was 34.2%. The major responses to nonhematologic toxicity were nausea or vomiting and alopecia. Conclusion The combination of topotecan and cisplatin is a feasible, well tolerated and active scheme in treatment of advanced squamous carcinoma of lung.
【CateGory Index】: R734.2
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved